OverviewSuggest Edit

Cidara Therapeutics is developing innovative therapies to treat life-threatening illnesses exacerbated by deficiencies of the human immune system. Its initial focus is on devastating fungal infections that often complicate cancer and transplant treatments.

TypePublic
Founded2013
HQSan Diego, CA, US
Websitecidara.com

Latest Updates

Employees (est.) (Feb 2020)68
Job Openings11
Share Price (Sept 2021)$2.3(+3%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Cidara Therapeutics

Jeffrey Stein

Jeffrey Stein

President and Chief Executive Officer, Director
Dan Burgess

Dan Burgess

Chairman of the Board
Taylor Sandison

Taylor Sandison

Chief Medical Officer
Paul Daruwala

Paul Daruwala

Chief Operating Officer
Neil Abdollahian

Neil Abdollahian

Chief Business Officer
Les Tari

Les Tari

Chief Scientific Officer
Show more

Cidara Therapeutics Office Locations

Cidara Therapeutics has an office in San Diego
San Diego, CA, US (HQ)
6310 Nancy Ridge Dr
Show all (1)

Cidara Therapeutics Financials and Metrics

Cidara Therapeutics Revenue

USD

Net income (FY, 2020)

(72.1m)

EBIT (FY, 2020)

(71.8m)

Market capitalization (23-Sept-2021)

110.9m

Closing stock price (23-Sept-2021)

2.3

Cash (30-Sept-2020)

45.5m

EV

74.7m
Cidara Therapeutics's current market capitalization is $110.9 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

8.8m12.7m12.9m14.1m16.2m15.9m

R&D expense

23.5m35.7m42.8m49.1m46.4m68.0m

Operating expense total

32.3m48.4m55.7m63.3m62.6m83.9m

EBIT

(32.3m)(48.4m)(55.7m)(63.3m)(41.7m)(71.8m)
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

62.6m85.4m60.8m74.6m50.3m

Accounts Receivable

321.0k

Prepaid Expenses

2.0m2.6m

Inventories

704.0k779.0k
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

58.1m122.3m64.5m51.7m29.3m24.6m82.2m78.0m54.3m52.2m89.0m83.8m57.4m44.6m73.8m64.3m54.8m45.5m

Accounts Receivable

215.0k321.0k288.0k41.0k

Prepaid Expenses

278.0k749.0k947.0k859.0k1.1m1.3m1.2m1.6m1.7m1.7m2.8m3.7m2.9m3.2m3.7m

Current Assets

58.4m123.1m115.4m97.5m88.2m80.6m91.3m79.8m66.2m69.0m106.0m92.0m60.3m47.7m77.5m80.6m70.0m60.2m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(32.2m)(48.2m)(55.7m)(59.0m)(41.1m)(72.1m)

Depreciation and Amortization

461.0k732.0k667.0k523.0k286.0k

Inventories

(487.0k)(76.0k)

Accounts Payable

3.1m642.0k(59.0k)(784.0k)6.6m
USDQ1, 2015

Financial Leverage

-3.5 x
Show all financial metrics

Cidara Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Cidara Therapeutics Online and Social Media Presence

Embed Graph

Cidara Therapeutics News and Updates

Cidara Therapeutics to Host Research and Development Day

Virtual event will highlight the broad potential of the Cloudbreak® platform and the commercial potential for rezafungin

Cidara Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, and Shane Ward as Chief Legal Officer and Corporate Secretary

Appointments add two biotech industry veterans each with over two decades of experience to Company’s management team Appointments add two biotech industry veterans each with over two decades of experience to Company’s management team

Cidara Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President…

Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and Animal Mycology (ISHAM) Asia Congress

SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present clinical and pr…

Cidara Therapeutics Presents New Analyses from Multiple Rezafungin Studies at ECCMID 2021

Oral presentation shows clinical data demonstrating clearance of infection in initial days of treatment of candidemia following one dose of rezafungin compared to multiple daily doses of standard of care

Cidara Therapeutics Provides Leadership Update

SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that James (Jamie) Levine has resign…
Show more

Cidara Therapeutics Blogs

Cidara Provides Corporate Update and Reports First Quarter 2021 Financial Results

SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months

Orphan Drug Designation Granted to Rezafungin in EU for the Treatment of Invasive Candidiasis

Orphan Drug Designation Granted to Rezafungin in EU for the Treatment of Invasive Candidiasis jcong Tue, 01/26/2021 - 09:42 Orphan Drug Designation Granted to Rezafungin in EU for the Treatment of Invasive Candidiasis January 26, 2021 at 9:43 AM EST This relea…

Cidara Therapeutics to Participate in Upcoming Investor Conferences

Cidara Therapeutics to Participate in Upcoming Investor Conferences Content Import Wed, 09/02/2020 - 08:02 Cidara Therapeutics to Participate in Upcoming Investor Conferences September 2, 2020 at 8:00 AM EDT This release is a backfill from a News Wire …

Cidara Provides Corporate Update and Reports Second Quarter 2020 Financial Results

SAN DIEGO , Aug. 13, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended

Cidara Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein , Ph.D., President and

Cidara Therapeutics Announces Formation of Scientific Advisory Board

Comprised of World-Renowned Experts in Virology, Fungal Diseases and Hematology SAN DIEGO , July 27, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or
Show more

Cidara Therapeutics Frequently Asked Questions

  • When was Cidara Therapeutics founded?

    Cidara Therapeutics was founded in 2013.

  • Who are Cidara Therapeutics key executives?

    Cidara Therapeutics's key executives are Jeffrey Stein, Dan Burgess and Taylor Sandison.

  • How many employees does Cidara Therapeutics have?

    Cidara Therapeutics has 68 employees.

  • Who are Cidara Therapeutics competitors?

    Competitors of Cidara Therapeutics include Alembic Pharmaceuticals, EMS Pharma and PPD.

  • Where is Cidara Therapeutics headquarters?

    Cidara Therapeutics headquarters is located at 6310 Nancy Ridge Dr, San Diego.

  • Where are Cidara Therapeutics offices?

    Cidara Therapeutics has an office in San Diego.

  • How many offices does Cidara Therapeutics have?

    Cidara Therapeutics has 1 office.